)
)
)
Akebia Therapeutics works to develop unique therapeutics that have the potential to set new standards of care for people living with kidney disease. Akebia is a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization. The company currently has two FDA-approved products, including Vafseo (vadadustat), an oral HIF-PH inhibitor approved for the treatment of anemia due to chronic kidney disease for patients on dialysis.
Year Founded
2007
Next catalyst (value inflection) update
Vafseo U.S. launch and label expansion updates
Expected time of next catalyst update
01/05/2025
City
Cambridge
Country
United States
Company CEO or top company official
John Butler
Development Phase of Primary Product
Multiple Products in Market
Exchange
NASDAQ
Lead Product in Development
Vafseo (vadadustat)
Market Cap
$445M
Therapeutic Area
Other
Website
http://akebia.com